vaccine prevents 408 469 cases of precancerous cervical lesions. Due to HPV vaccination the incidence of CC is reduced by1858 cases, which corresponds to 31 588 years of life saved in the vaccinated cohort. The cost of an additional life-year saved is 10,166 € (405,535 rubles), and the cost of averted CIN case is 786 € (31,360 rubles). CONCLUSIONS: Vaccination with Human Papillomavirus recombinant vaccine seems a cost-effective option in Russia. Ghent University, Ghent, Belgium, 4 Sanofi Pasteur MSD, Lyon, France OBJECTIVES: Pertussis incidence has been increasing in adolescents and adults in the last two decades with transmission to vulnerable young infants. This epidemiological changing has raised interest in the cost-effectiveness of booster vaccination (extra administration of a vaccine after an earlier dose). A critical review of economic evaluations of pertussis booster vaccination was performed in order to develop recommendations for future studies. This review illustrates specific challenges encountered in economic evaluations of vaccination programmes.
OBJECTIVES:
Rotavirus infection causes severe gastroenteritis in children worldwide. Its disease burden has been reduced in countries where mass rotavirus vaccination programmes have been introduced. England and Wales (E&W) have not yet implemented such a mass vaccination programme, but are currently re-evaluating its potential cost-effectiveness. Our study uses a dynamic model to predict the epidemiological and economical effect of such a mass vaccination programme in E&W beginning in the autumn of 2011. METHODS: A previously published agestructured dynamic model was upgraded and parameterised with country-specific data for the introduction of the oral rotavirus pentavalent vaccine. We report the impact of vaccination on disease incidence reduction, timing of seasonal epidemics and herd immunity levels. The model was then used to assess whether a mass vaccination of RotaTeq is cost-effective and affordable for E&W. RESULTS: Our results predict that vaccination can reduce the burden of severe disease by 70% and delay the epidemic peak by two and a half months with coverage of 95%. Our calculations further show that herd immunity accounts for about a quarter of the reduction in incidence. If the pentavalent vaccine-induced immunity does not wane over five years, severe disease in children under five years of age is eliminated within two years after the introduction of vaccination. The probability of a mass vaccination strategy being cost-effective is presented under likely vaccine waning scenarios, administration cost assumptions and possible dose prices. CONCLUSIONS: This work allows policymakers to determine both the epidemiological impact and cost implications of a mass vaccination programme against rotavirus with the pentavalent vaccine in England and Wales. Although long considered unlikely to be cost-effective in E&W using static models, the pentavalent vaccine demonstrates a significant impact in reducing rotavirus cases at acceptable levels of cost-effectiveness when using appropriate modelling techniques. 
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OBJECTIVES:
To assess the cost-effectiveness of universal rotavirus immunization, explicitly the use of Rotateq® and affordability of implementing rotavirus immunization based on the Global Alliance for Vaccines and Immunization (GAVI)-subsidized vaccine price in the context of Vietnamese health care system for the next 5 years. METHODS: An age-structured cohort model was developed for the 2009 Vietnamese birth cohort and applied a 5-year time horizon with time cycle of 1 month for Ͻ 1-year-old children and annually thereafter. Results from no vaccination and vaccination were compared. Outcomes included rotavirus episodes requiring home-treatment, outpatient visits, hospitalizations and deaths. Multiple outcomes per rotavirus infection are possible in the model. Acceptability and affordability analyses were done using Monte Carlo simulations. Costs were expressed in 2009 US$. RESULTS: Rotavirus immunization would not completely protect under-five-year-old children against rotavirus infection due to partial nature of vaccine immunity, however, would effectively reduce rotavirus severe cases by ϳ55%. Under the GAVI-subsidized price, the minimum vaccination budget would be US$1.6 million annually. In the base-case, the incremental cost per quality-adjusted-life-year (QALY) was US$665 from health care perspective, ϽVietnam-ese per-capita-GDP in 2009. Affordability results showed that at the GAVI-subsidized vaccine price, rotavirus vaccination could be affordable in Vietnam. CONCLUSIONS: Rotavirus immunization in Vietnam would be a cost-effective health intervention. However, it only becomes affordable under the GAVI's financial support. Vaccine price is the most crucial factor to decision-makers regarding introducing this vaccine into the country's immunization. Given the high underfive mortality rate, results showed that rotavirus immunization is the "best hope" for prevention of rotavirus-related diarrhoeal disease in Vietnam. In the next five years, Vietnam is definitely in debt to external financial support in implementing rotavirus vaccination. It is recommended that new and cheaper rotavirus vaccine candidates be developed to speed up rotavirus vaccines introduction in the developing world. Vaccination of elderly (65 and older) population against Streptococcus pneumonia is recommended in Poland but not publicly funded. Therefore coverage rates for pneumococcal vaccine have remained very low (less than 1%) meaning that no benefit of the vaccine has been felt in Poland and individuals remain largely unprotected. OBJECTIVES: An analysis was designed to analyse the cost-effectiveness of implementing a public vaccination programme in the elderly considering a 50% reimbursement of a 23-valent polysaccharide vaccine (PPV23) by the public health care payer: Narodowy Fundusz Zdrowia (NFZ). METHODS: To do so, a semidynamic Markov model with a 1-year cycle length was developed, allowing up to 10 cohorts to enter the model over the lifetime horizon. The model was populated with demographic, epidemiological and cost data from Polish sources or when unavailable, from international literature. The analysis included routine vaccination of all elderly or high-risk (HR) elderly versus no vaccination. Deterministic and probabilistic sensitivity analyses (DSA and PSA, respectively) were conducted to assess the robustness of the cost-effectiveness results. RESULTS: The vaccination program targeting all elderly in Poland would avoid 8935 pneumococcal infections, 2542 hospitalisations, 671 deaths; for HR elderly the program would avoid 5886 infections, 1673 hospitalisations and 441 deaths. The incremental cost per QALY gained for vaccination in all elderly was PLN 3382 and was PLN 2148 for HR elderly. Ratios were even lower when actual in and outpatients' costs instead of reimbursed costs were considered. Finally, ratios estimated in the base case and the sensitivity analyses, were well below the gross domestic product (GDP) per capita (i.e. PLN 37,055). CONCLUSIONS: This analysis suggests that vaccinating all elderly regardless of risk status with a 23-valent pneumococcal vaccine is highly costeffective and supports the continued recommendation of pneumococcal vaccines, as well as their public funding in Poland. OBJECTIVES: According to World Health Organization, pneumococcal related diseases is a major public health concern in the world, especially for those under 2 years of age and older adults. The objective of this analysis is to evaluate the cost effectiveness of vaccinating the Brazilian population 65 years of age and older with the 13-valent pneumococcal conjugate vaccine (PCV 13) in comparison to the 23-valent pneumococcal polysaccharide vaccine (PPV 23), each as a single dose, from the public payer perspective. METHODS: In order to estimate the costs and the impact of the pneumococcal disease over a 35-year time horizon period, including invasive pneumococcal disease, hospitalized pneumonia and non complicated pneumonia, a patient level microsimulation model simulating vaccination and outcomes of one cohort of 12,653,613 individuals over 65 years of age was adapted to the Brazilian public health care system. The probabilities and direct medical costs were extracted from literature review and DATASUS for January 2011, with costs presented in US$ 2010. The effectiveness measures were expressed as cases of pneumococcal diseases avoided, overall deaths avoided, and life years (LYs) saved. Probabilistic sensitivity analyses were conducted considering key variables. A discount rate of 5% was applied. RESULTS: Vaccinating with PCV13 prevents 349 additional cases of acute meningitis, 1,589 cases of invasive pneumococcal disease, 100,158 hospitalized pneumonia, 12,954 non complicated pneumonia and 30,904 deaths, saving 139,189,74 LYs compared to PPV23 over 35 years. The total costs including vaccination costs and medical costs resulted in US$135,625,000 less for PCV13 compared to PCV23 (US$5,875,625,000 vs. US$5,740,000,000). The model showed robustness through sensitivity analyses. CONCLUSIONS: The analysis suggests that vaccinating adults with PCV13 in Brazil is cost-saving compared to PPV23. The results in economic and disease burden are substantial and they support the decision making in favor of PCV13 for its high impact in public health. OBJECTIVES: Systemic Candida infections (SCI) occur predominantly in intensive care unit (ICU) patients and are a common cause of morbidity and mortality. The increasing prevalence of SCI caused by Candida non-albicans species and higher resistance to fluconazole and azoles in general have prompted changes in the management of SCI. Current guidelines tend to favour treatment initiation with a broad spectrum antifungal such as an echinocandin with subsequent switch to fluconazole if isolates are sensitive (de-escalation) over the traditional first-line treatment with fluconazole (escalation). Cost-effectiveness of de-escalation strategy versus escalation in patients with SCI was evaluated from the UK NHS perspective. METHODS: Cost-effectiveness was estimated using decision analysis based on clinical and microbiological data from pertinent studies. The model horizon was 42 days, and was extrapolated to cover a life time horizon. RESULTS: In patients with fluconazole-resistant isolates, de-escalation avoids 30% more deaths and successfully treats 23% more patients than escalation, with cost savings of £1621 per treated patient. In the overall population with SCI, initial treatment with micafungin results in 1.2% fewer deaths at a marginal cost of £740 per patient alive. Over a lifetime horizon, the incremental cost effectiveness of de-escalation compared with escalation is £15,522 per life-year and £25,673 per QALY. Univariate analyses indicate that the incremental costs per QALY of de-escalation are highly sensitive to the fluconazole-susceptibility profile, late mortality in fluconazoleresistant infections, fluconazole clinical success rate, excess hospitalization, life expectancy, underlying diseases and follow-up costs. CONCLUSIONS: The de-escalation strategy is associated with better clinical outcomes and improved survival, particularly among patients with fluconazole-resistant Candida strains. De-escalation from initial treatment with micafungin is a cost effective alternative to traditional escalation approach from a UK NHS perspective with a differential cost per QALY below the recognised willingness to pay threshold of £30,000.
PIN73 MODELING THE LONG TERM CLINICAL OUTCOMES AND HEALTH CARE COST IMPACT OF INITIATING TREATMENT WITH ATAZANAVIR/R COMPARED WITH DARUNAVIR/R, LOPINAVIR/R AND EFAVIRENZ FOR HIV-1 INFECTED TREATMENT-NAÏVE PATIENTS: COUNTRY RESULTS FOR ITALY, SPAIN, PORTUGAL AND UK
PIN76 COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPV23) PNEUMOCOCCAL VACCINES FOR SENIOR ADULTS IN BRAZIL
PIN77 COST EFFECTIVENESS OF DE-ESCALATION FROM MICAFUNGIN IN THE TREATMENT OF PATIENTS WITH SYSTEMIC CANDIDA INFECTIONS COMPARED TO TRADITIONAL ESCALATION FROM FLUCONAZOLE
